DiaSorin S.p.A. (VIE:DIAS)

Market Cap	3.59B
Revenue (ttm)	1.21B
Net Income (ttm)	184.11M
Shares Out	n/a
EPS (ttm)	3.41
PE Ratio	19.52
Forward PE	15.41
Dividend	1.20 (1.88%)
Ex-Dividend Date	May 19, 2025

Volume	n/a
Average Volume	7
Open	67.40
Previous Close	64.62
Day's Range	66.68 - 67.40
52-Week Range	58.60 - 107.25
Beta	n/a
RSI	66.62
Earnings Date	Mar 13, 2026

About DiaSorin

DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, endocrinology, gastrointestinal infections, autoimmunity, hypertension, emergency/sepsis, bone metabolism, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urin...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1968
• Employees: 3,308
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: DIAS

Financial Performance

In 2024, DiaSorin's revenue was 1.19 billion, an increase of 3.24% compared to the previous year's 1.15 billion. Earnings were 188.11 million, an increase of 17.68%.